Brandon (Host)

speaker

390 appearances 3 recordings 1 series first heard Jun 2026 last heard 16 Jul

Brandon (Host)’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months

Recordings per month over the last 12 months — 3 in all, peaking in Jul 2026 with 2.

Appearances

newest first · ▶ plays the moment

Latent Space: The AI Engineer Podcast · 🔬 The Coolest Diffusion Research Isn't in LLMs — Evan Feinberg & Sergey Edunov, Genesis Molecular AI · 1 Jul 2026 podcast

And yeah, how do you interact with just like a single structure versus like an ensemble?

And I don't know if that question even makes sense, but...

Sorry, going in that direction, you know, just to give a phrase, I'm jumping into a technical rabbit hole here, but just because you have a pose also, I mean, there's like entropic and entropic contributions and predicting binding affinity is not just about getting the energy right, but actually is this even likely to make it into the binding pocket and is it like to live there long term?

So it's much more than just, you know, affinity, potency prediction is much more than just...

Is this the right pose?

But does this have the broader properties it needs to be a long-lived molecule in this state?

And how do you kind of deal with those things too?

How long have you been working towards this specific goal?

I mean, I'm curious.

This is not something that you broadly hear in the community talk about when people do say to have decided doing from is sort of the canonical benchmark.

And

I've never heard someone say one instrument before is the cutoff until like reading things coming out of Genesis.

How long have you decided this is the number we need to hill climb on?

How direct is this focus been?

And in like the evolution of the company, I'm just wondering, like, how did this come about?

Right.

So, I mean, there's a lot of really smart med chemists who are also, you know, who think very carefully about benchmarks and people I respect very much and who also have prosecuted actual drug discovery programs.

So, I know, I'm just kind of curious, like, why hasn't this become part of the community?

Is this literally just that the community has never been able to succeed at winning some benchmarks that they kind of settled it to as a, okay, something we can aspire to?

Or, I don't know, just...

Showing 221–240 of 390 · page 12 of 20